restarting tirzepatide after 4 weeks Stopping Tirzepatide: Weight Rebound & Clinical Considerations – PlexusDx Mounjaro Pen: UK Guidance for

It is a GLP-1 agonist

Compared to the control, sperm count significantly decreased in the MSG (44% reduction

Months 46: Building Momentum and Lifestyle Integration The 46 month window typically shows cumulative weight loss ranging from 1015% of starting body weight for most patients on consistent tirzepatide therapy

ResMed CEO: Big Pharma is squarely focused on GLP-1 medications right now Image courtesy of ResMed ResMed CEO Mick Farrells stance on the issue is that the latest advances in both Big Tech and Big Pharma can potentially bring incredible numbers of new patients into the healthcare system where ResMed is uniquely positioned to provide ongoing care at home. Patients are voting with their wallets and respiratory therapists and physicians are voting with their recommendations and their prescriptions. During the companys first-quarter earnings call, Farrell said the company is laser-focused on growing the market to help people get on the therapy they need and on a pathway to better sleep, better health, and better long-term care